Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia: Value of polymerase chain reaction and limitations of flow cytometry

American Journal of Clinical Pathology

Volumn 111, Issue 6, 1999, Pages 759-766

  Kallakury, Bhaskar V S ^a   Hartmann, Dan Paul ^a   Cossman, Jeffrey ^a   Gootenberg, Joseph E ^a   Bagg, Adam ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell precursor acute lymphoblastic leukemia; Flow cytometry; Hematogones; Minimal residual disease; Polymerase chain reaction

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; DNA; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN HEAVY CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FOLLOW UP; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLYMPHOCYTE; REMISSION;

EID: 0033046506     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.6.759     Document Type: Article

References (26)

1. Imamura N, Kuramoto A. Detection of minimal residual disease in acute lymphoblastic leukemia by flow cytometry with monoclonal antibodies. Am J Hematol. 1991;38:332-334.
2. Davis RE, Longacre TA, Combleet PJ. Hematogones in the bone marrow of adults: immunophenotypic features, clinical settings and differential diagnosis. Am J Clin Pathol. 1994;102:202-211.
3. Caldwell CW, Poje E, Helikson MA. B-cell precursors in normal pediatric bone marrow. Am J Clin Pathol. 1991;95:816-823.
4. Longacre TA, Foucar K, Crago S, et al. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood. 1989;73:543-552.
5. Muehleck SD, McKenna RW, Gale PF, et al. Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy. Am J Clin Pathol 1983;79:277-284.
6. Schmitt C, Eaves CJ, Lansdorp PM. Expression of CD34 on human B cell precursors. Clin Exp Immunol. 1991;85:168-173.
7. Ryan DH, Kossover S, Mitchell S, et al. Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens. Blood. 1986;68:417-425.
8. Ryan DH, Chapple CW, Kossover SA, et al. Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors. Blood. 1987;70:814-821.
9. Hokland P, Nadler LM, Griffin JD, et al. Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984;64:662-666.
10. Greaves MF, Hariri G, Newman RA, et al. Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood. 1983;61:628-639.
11. Greaves M, Delia D, Janossy G, et al. Acute lymphoblastic leukemia associated antigen expression on non-leukemic "lymphoid cells." Leukemia Res. 1980;4:15-32.
12. Hirt A, Morell A, Frei H, et al. Proliferation of lymphoid precursor cells in the bone marrow of patients with various disorders of the immune system. Exp Hematol. 1988;16:38-41.
13. Stekhoven JHS, Langenhuysen CAM, Bakkeren JAJM, et al. Morphology and incidence of the "post-therapeutic lymphoid cells" in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1986; 124:46-52.
14. van den Doel LJ, Pieters R, Huismans DR, et al. Immunological phenotype of lymphoid cells in regenerating bone marrow of children after treatment for acute lymphoblastic leukemia. Eur J Hematol 1988;41:170-175.
15. Ifrah N, Boucheix C, Marie JP, et al. Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia: Marker analysis and significance. Cancer. 1986;58:2018-2022.
16. Anastasi J, Vardiman JW, Rudinsky R, et al. Direct correlation of cytogenetic findings with cell morphology using in-situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood. 1991;77:2456-2462.
17. Nolan C, ed. Molecular Cloning: A Laboratory Manual. New York, NY: Cold Spring Harbor Laboratory Press, 1989.
18. Sioutos N, Bagg A, Michaud GY, et al. Polymerase chain reaction versus Southern blot hybridization: detection of immunoglobulin heavy-chain gene rearrangements. Diagn Mol Pathol. 1995;4:8-13.
19. Benhatter J, Delacretaz F, Martin P, et al. Improved polymerase chain reaction detection of clonal T-cell lymphoid neoplasms. Diagn Mol Pathol. 1995;4:108-112.
20. Wells DA, Sale GE, Shulman HM, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol. 1998;110:84-94.
21. Yamada M, Wasserman R, Lange B, et al. Minimal residual disease in childhood B-lineage lymphoblastic leukemia: persistence of leukemic cells during the first 18 months of treatment. N Engl J Med. 1990;323:448-455.
22. Beishuizen A, Verhoeven MAJ, van Wering ER, et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood. 1994;83:2238-2247.
23. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukemia. Br J Hematol. 1993;83:412-418.
24. Steenbergen EJ, Verhagen OJHM, van Leeuwen EF, et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia. 1995;9:1726-1734.
25. Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Hematol. 1997;98:140-146.
26. Roberts WM, Estrov Z, Ouspenskaia MV, et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997;336:317-323.